Zelira Therapeutics Ltd has released a press release.
Zelda Focuses Clinical Trial Activity
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- US Autism Observational Study Underway
- First Patient Dosed in Zelda Insomnia Trial
- Zelda Forms New Partnership to Access German Market
- June 2018 Quarterly Report
- Commencement of New Managing Director
Later from Zelira Therapeutics
- September 2018 Quarterly Report
- Opioid reduction clinical trial with St Vincents Hospital
- ZLD to Invest in Development of Oral Spray Formulations
- December 2018 Quarterly Report and Board Transition
- Appendix 4D & FY19 Interim Financial Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics